10-Q - MBX Biosciences, Inc. (0001776111) (Filer)

8-K - MBX Biosciences, Inc. (0001776111) (Filer)

8-K - MBX Biosciences, Inc. (0001776111) (Filer)

Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last subject last visit in Phase 1 trial of MBX 1416 anticipated by late November; topline results to be reported in early January 2025 Enrollment of Phase 2 Avail™ trial of MBX 2109 in hypoparathyroidism on track to complete in Q1 2025; topline results anticipated in Q3 2025 Strong cash position, with $277.1 million expected to support operations into mid-2027 CARMEL, Ind., Nov. 07, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies fo

CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its management team will participate in the following upcoming investor conferences: Guggenheim Inaugural Healthcare Innovation Conference Date: Tuesday, November 12, 2024Format: Fireside chatTime: 3:30 p.m. ESTLocation: Boston, MA Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024Format: Fireside chatTime: 3:00 p.m. ESTLocation: New York, NY Jefferies London Healthcare Conference Date: Wedne

CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX) ("MBX Biosciences"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the closing of its previously announced upsized initial public offering of 11,730,000 of its common stock at a price to the public of $16.00 per share, which includes 1,530,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The aggregate gross proceeds to MBX Biosciences from the offering were approximately

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

Guggenheim initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $44.00

Stifel initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $40.00

Jefferies initiated coverage of MBX Biosciences with a rating of Buy and set a new price target of $35.00

JP Morgan initiated coverage of MBX Biosciences with a rating of Overweight and set a new price target of $30.00